Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer.
Vera HöllrieglNina Petoussi-HenssKerstin HürkampJuan Camilo Ocampo RamosWei Bo LiPublished in: EJNMMI physics (2021)
The biokinetic modelling of 223Ra and its progeny may help to predict their distributions in patients after administration of Xofigo®. The organ dose coefficients of this work showed some variation to the values reported from clinical studies and an earlier compartmental modelling study. The dose to the bone endosteum was found to be lower by a factor of ca. 3 than previously estimated.
Keyphrases
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- chronic kidney disease
- newly diagnosed
- small cell lung cancer
- squamous cell carcinoma
- peritoneal dialysis
- prognostic factors
- disease activity
- bone mineral density
- interstitial lung disease
- patient reported outcomes
- combination therapy
- bone regeneration
- replacement therapy